TrialJournal of neurology2024

104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).

Benedikt Schoser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.